Table 1.
Baseline characteristics of the included studies in the meta-analysis
| Authors | Design | Year | Study period | Number of patients | Median age | Endometrioid histology | Non endometrioid | MI | LVI | Grade 1 | Grade 2 | Grade 3 | Total MIC/ITCs patients | MIC/ITC (%) | Technique |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim et al. [19] | Prospective cohort | 2013 | 2005–2011 | 425 | 58 | 415 | 10 | None: 241; < 50%: 184 | Yes: 58; no: 367 | 302 | 108 | 15 | 12 (9 ITCs) (3 MIC) | 3 | Ultrastaging (H&E + IHC: Anticytokeratin AE1/AE3) |
| Kim et al. [20] | Retrospective cohort | 2013 | 2005–2011 | 508 | 61 | 413 | Serous: 62; clear cell: 12; carcinosarcoma: 21 | None: 242; < 50%: 198; ≥ 50%:68 | Yes: 132; no: 376 | 261 | 116 | 131 | 23 (19 ITCs) (4 MIC) | 5 | Ultrastaging (H&E + IHC: Anticytokeratin AE1/AE3) |
| Erlanki et al. [21] | Retrospective cohort | 2010 | 2003–2006 | 47 | 60 | 37 | Adenosquamous: 7; serous papillary: 2; clear cell: 1 | None: 9; < 50%: 19; > 50%: 19 | Yes: 4; no: 40; no data: 3 | 15 | 21 | 8 | 7(MIC) | 15 | Ultrastaging (H&E + IHC: Standard ABC + Anticytokeratin AE1/AE3) |
| Clair et al. [22] | Retrospective cohort | 2015 | 2005–2013 | 844 | 61 | 724 | Serous: 104; clear cell: 16 | None: 422; < 50%: 310; ≥ 50%:112 | Yes: 201; no: 618; no data: 25 | 479 | 177 | 188 | 44 (23 ITCs) (21 MIC) | 5 | Ultrastaging (H&E + IHC: Anticytokeratin AE1/AE3) |
| Todo et al. [23] | Retrospective cohort | 2016 | 1997–2014 | 61 | 57 | 52 | 9 | < 50%: 29; ≥ 50%:32 | Yes: 15; no: 46 | 28 | 7 | 17 | 9 (6 ITCs) (3 MIC) | 15 | Ultrastaging (H&E + IHC: AE1/AE3 monoclonal antibody staining using an automated immunostainer) |
| Plante et al. [24] | Prospective cohort | 2017 | 2010–2015 | 519 | 64 | 448 | Serous: 36; carcinosarcoma: 25; clear cell: 7; other: 3 | None: 125; < 50%: 234; ≥ 50%:160 | Yes: 142; no: 362; no data: 15 | 260 | 150 | 109 | 42 (31 ITCs) (11 MIC) | 8 | Ultrastaging (H&E + IHC: Cytokeratin AE1/AE3) |
| Piedimonte et al. [27] | Retrospective case–control | 2018 | 2012–2018 | 41 | 64 | 41 | 0 | > 50%:16 | 17 | No data | No data | No data | 23 (11 ITCs) (12 MIC) | 56 | Ultrastaging (H&E + IHC: Cytokeratin-based) |
| Ignatov et al. [26] | Prospective cohort | 2019 | 2000–2017 | 428 | 69 | 399 | 26 | > 50%: 152; < 50%: 240 | No data | 145 | 174 | 100 | 126 (MIC) | 29 | Ultrastaging |
| Summary | Meta-analysis | 2873 | 62 | 2529 | 1490 | 753 | 568 | 17 |
SLN sentinel lymph node, MM micrometastases, ITCs isolated tumor cells, RT-PCR reverse transcription polymerase chain reaction, H&E hematoxylin and eosin; IHC immunohistochemistry, MI myometrial invasion, LVI lymphovascular space invasion, ABC avidin–biotin–peroxidase complex